SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on August 14, 2003; DOI 10.1182/blood-2003-06-1867. This Article Full Text (PDF) All Versions of this Article: 2003-06-1867v1 102/12/4137    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Zhao, Y. Articles by Gilboa, E. Search for Related Content PubMed PubMed Citation Articles by Zhao, Y. Articles by Gilboa, E. Social Bookmarking                   What's this? Submitted June 11, 2003 Accepted August 4, 2003 Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T cell responses and tumor immunity Yangbing Zhao, David Boczkowski, Smita K Nair, and Eli Gilboa* Center for Genetic and Cellular Therapies, Department of Surgery, Duke University Medical Center, Durham, NC, USA * Corresponding author; email: e.gilboa{at}cgct.duke.edu. Induction of potent and sustained antiviral or antitumor immunity is dependent on the efficient activation of CD8+ and CD4++ T cells. While dendritic cells constitute a powerful platform for stimulating cellular immunity, presentation of endogenous antigens by dendritic cells transfected with nucleic acid-encoded antigens favors the stimulation of CD8+ T cells over that of CD4+ T cells. A short incubation of mRNA transfected dendritic cells with antisense oligonucleotides directed against the invariant chain enhances the presentation of mRNA encoded class II epitopes and activation of CD4+ T cell responses in vitro and in vivo. Immunization of mice with the antisense oligonucleotide treated dendritic cells stimulates a more potent and longer lasting CD8+ CTL response and enhances the antitumor efficacy of dendritic cell-based tumor vaccination protocols. Transient inhibition of invariant chain expression represents a simple and general method to enhance the stimulation of CD4+ T cell responses from endogenous antigens. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. A. Barber, T. Zhang, B. A. Gagne, and C. L. Sentman NK Cells Negatively Regulate Antigen Presentation and Tumor-Specific CTLs in a Syngeneic Lymphoma Model J. Immunol., May 15, 2007; 178(10): 6140 - 6147. [Abstract] [Full Text] [PDF] L. M. Rimsza, R. A. Roberts, E. Campo, T. M. Grogan, S. Bea, I. Salaverria, A. Zettl, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions Blood, February 1, 2006; 107(3): 1101 - 1107. [Abstract] [Full Text] [PDF] J. Lee, M. Fassnacht, S. Nair, D. Boczkowski, and E. Gilboa Tumor Immunotherapy Targeting Fibroblast Activation Protein, a Product Expressed in Tumor-Associated Fibroblasts Cancer Res., December 1, 2005; 65(23): 11156 - 11163. [Abstract] [Full Text] [PDF] R. Kennedy, A. H. Undale, W. C. Kieper, M. S. Block, L. R. Pease, and E. Celis Direct Cross-Priming by Th Lymphocytes Generates Memory Cytotoxic T Cell Responses J. Immunol., April 1, 2005; 174(7): 3967 - 3977. [Abstract] [Full Text] [PDF] D. W. O'Neill, S. Adams, and N. Bhardwaj Manipulating dendritic cell biology for the active immunotherapy of cancer Blood, October 15, 2004; 104(8): 2235 - 2246. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020